-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bausch+Lomb and Clearside Biomedical recently announced that the U.
It is worth mentioning that Xipere is the first product approved by the US FDA to be administered by suprachoroidal space (SCS) injection, and it is also the first to be approved for the treatment of uveitis-related macular edema
Macular edema is the accumulation of fluid in the macula, causing swelling of the retina and distortion of vision.
SCS Microinjector® technology provides a unique channel for the treatment of posterior ocular diseases that often threaten vision
This approval is based on data from the Phase 3 clinical study PEACHTREE
The data showed that compared with sham controls, Xipere treatment resulted in statistically significant and clinically significant improvements in visual acuity in patients with non-infectious uveitis-related macular edema, and improvements in all anatomical sites of uveitis
Xipere (triamcinolone acetonide eye drops) is used for suprachoroidal injection.
Uveitis is a group of ocular inflammatory diseases and one of the main causes of vision loss, affecting approximately 350,000 patients in the United States and more than 1 million patients worldwide
Note: The original text has been deleted
Original source: Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
